- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NATTOPHARMA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 62,58 | -2,46 % | Ionis, Alnylam, BioMarin up as Citi starts at Buy on catalyst and growth outlook | ||
| CSPC PHARMA | 0,805 | -1,20 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE KAT6 INHIBITOR (SYH2095 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA | ||
| SELLAS LIFE SCIENCES | 6,540 | 0,00 % | SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses | ||
| ACADIA PHARMACEUTICALS | 17,565 | -3,09 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 26,900 | 0,00 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results | Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 443,30 | +0,57 % | Truist raises Madrigal Pharmaceuticals stock price target on MASH survey | ||
| OPUS GENETICS | 3,680 | 0,00 % | Opus Genetics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets | Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,204 | +3,24 % | Savara: Positive Studiendaten zu Molgramostim bei seltener Lungenerkrankung | ||
| GALECTIN THERAPEUTICS | 1,950 | +8,94 % | Galectin Therapeutics GAAP EPS of -$0.08 misses by $0.02 | ||
| BIODEXA PHARMACEUTICALS | 3,115 | -0,48 % | Biodexa Pharmaceuticals PLC: Biodexa issues letter to Shareholders | May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or... ► Artikel lesen | |
| CGN MINING | 0,364 | +2,82 % | CGN MINING (01164): MATTERS RELATING TO RULE 13.92(2) OF THE LISTING RULES | ||
| PHOTOCURE | 5,950 | +6,25 % | Photocure: AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study | OSLO, Norway, May 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the American Urological... ► Artikel lesen | |
| ARCTICZYMES TECHNOLOGIES | 1,815 | -0,27 % | ArcticZymes Technologies ASA: ArcticZymes Technologies Delivers 36% Sales Growth in Q1 2026, with Molecular Tools Rebound and Biomanufacturing Momentum | ||
| NEURIZON THERAPEUTICS | 0,035 | 0,00 % | Neurizon Therapeutics Gains Ethics Approval for NUZ-001 Oral Liquid Phase 1 Study |
Das Unternehmen NATTOPHARMA ASA kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NATTOPHARMA ASA finden Sie auf Wallstreet Online.